Optellum Unveils Multimodal AI Platform for Lung Cancer Diagnosis at 2024 ASCO

Optellum, a global leader in AI-driven clinical decision support for early lung cancer diagnosis, has launched its multimodal therapy AI guidance platform for life science research. The novel AI software and scientific results, showing potential to optimize curative lung cancer treatment, will be showcased for the first time at the 2024 ASCO Annual Meeting in Chicago.

Lung cancer often shows no symptoms until it reaches an advanced stage, leaving patients with limited treatment options and less favorable outcomes. However, by continuous automated analysis of the 90 million CT scans US patients receive yearly, it may be possible to create an “early detection system”. Optellum's Virtual Nodule Clinic, the first FDA-cleared decision support for early-stage lung cancer, integrates a Patient Discovery AI based on Natural Language Processing with a clinically validated Lung Cancer Prediction (LCP) score based on imaging AI/Radiomics. This combination assists clinicians in identifying at-risk patients across health systems and prioritizing them for follow-up interventions, enhancing the chances of early detection and treatment.

Early diagnosis offers patients curative treatment options. Unfortunately, some 30% to 60% of Stage I-II NSCLC patients will experience recurrence after surgery. Accurate prognosis of recurrence risk could enable thoracic oncology teams to optimize treatment early, for example, by tailoring the extent of surgical resection and ensuring neo-adjuvant and peri-operative treatments are offered to those at risk. 

For drug developers, this may enable risk-stratifying populations to increase treatment rates, expand indications to earlier stages, and predict treatment response, thus enhancing the overall effectiveness of therapeutic interventions.

Optellum showcases their precision lung cancer care AI solutions at the American Society for Clinical Oncology (ASCO) 2024 Annual Meeting. In the ASCO scientific program, Optellum’s clinical partners will present results of AI-guided recurrence prognosis in Stage I-III NSCLC from multi-modal pre-surgical data, showing significantly increased sensitivity for recurrence compared to traditional staging methods. The Optellum AI solutions will also be demoed at the CancerLinQ booth and ConcertAI booth. The investigator of the National Lung Screening Trial (NLST) at the National Cancer Institute, explains the importance of accurate prognosis in driving treatment decisions, highlighting the effectiveness of Optellum's non-invasive radiomic tools in optimizing early patient care.

The multi-modal AI platform aims to become the ‘operating system’ that guides precision lung cancer care across the patient journey, from early identification to predicting response and monitoring. Neo-adjuvant therapies are real game changers. Together with our medtech and biopharma partners, we leverage the power of AI to help democratize access to life-saving early diagnosis and precision treatment for every patient who can benefit.

Market analysts at Vantage Market Research see significant potential for the Lung Cancer Screening Software market. The escalating incidence of lung cancer worldwide, prompting healthcare providers to seek innovative solutions for early detection and intervention. Lung cancer is the leading cause of cancer-related deaths globally, resulting in the highest mortality rates among both men and women, the imperative for effective screening technologies has never been greater. The market is driven by the expanding smoking population, advancements in screening technologies, and governmental initiatives aimed at bolstering early detection efforts. For instance, according to WHO, smoking is the primary cause of lung cancer, accounting for approximately 85% of all cases. Consequently, the market is witnessing heightened investments in research and development aimed at enhancing the accuracy and efficiency of screening software. The sector is poised to witness a 19.2% growth rate, reaching a staggering USD 146.32 Million by 2032.